BiotechTube

Escitalopram + Placebo oral tablet

ApprovedActive
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Obsessive-Compulsive Disorder/High Compulsive Individuals

Conditions

Obsessive-Compulsive Disorder/High Compulsive Individuals, Healthy Individuals

Trial Timeline

Apr 1, 2020 → Dec 31, 2027

NCT ID
NCT04336228

About Escitalopram + Placebo oral tablet

Escitalopram + Placebo oral tablet is a approved stage product being developed by Lundbeck for Obsessive-Compulsive Disorder/High Compulsive Individuals. The current trial status is active. This product is registered under clinical trial identifier NCT04336228. Target conditions include Obsessive-Compulsive Disorder/High Compulsive Individuals, Healthy Individuals.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04336228ApprovedActive

Competing Products

8 competing products in Obsessive-Compulsive Disorder/High Compulsive Individuals

See all competitors
ProductCompanyStageHype Score
Bitopertin + Placebo + SSRIRochePhase 2
52
pregabalin + PlaceboPfizerApproved
84
Sertraline + Levetiracetam + PlaceboUCBPhase 2/3
62
Valbenazine + PlaceboNeurocrine BiosciencesPhase 2
49
Troriluzole + PlaceboBiohavenPhase 3
72
Troriluzole + PlaceboBiohavenPhase 3
72
Troriluzole + PlaceboBiohavenPhase 2/3
60
Nitrous Oxide + NitrogenBrain BiotechPhase 2
44

Other Products from Lundbeck

VortioxetineApproved
82
memantine + memantine + placeboApproved
82
escitalopram + escitalopramApproved
82
BrexpiprazoleApproved
82
losartan (drug)Approved
82